Search

Your search keyword '"SAKAMOTO, Minoru"' showing total 33 results

Search Constraints

Start Over You searched for: Author "SAKAMOTO, Minoru" Remove constraint Author: "SAKAMOTO, Minoru" Database Complementary Index Remove constraint Database: Complementary Index
33 results on '"SAKAMOTO, Minoru"'

Search Results

1. A 1179-yr (417–1595 CE) tree-ring oxygen isotope chronology for northern Japan validated using the 774–775 CE radiocarbon spike.

3. A 2600-year summer climate reconstruction in central Japan by integrating tree-ring stable oxygen and hydrogen isotopes.

4. Prolonged production of 14C during the ~660 BCE solar proton event from Japanese tree rings.

5. HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers.

6. Hepatitis B virus (HBV)‐infected patients with low hepatitis B surface antigen and high hepatitis B core‐related antigen titers have a high risk of HBV‐related hepatocellular carcinoma.

7. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.

8. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.

9. Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma.

10. Liver stiffness measurement for risk assessment of hepatocellular carcinoma.

12. Deep sequencing analysis of variants resistant to the non-structural 5 A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection.

13. Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging.

14. Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.

15. Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.

16. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.

17. Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection.

18. Causes of Thrombocytopenia in Chronic Hepatitis C Viral Infection.

19. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.

20. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.

21. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.

22. Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy.

23. Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy.

24. Aging of wood: Analysis of color changes during natural aging and heat treatment.

25. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

26. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: Data mining analysis.

27. Targeting Lipid Metabolism in the Treatment of Hepatitis C Virus Infection.

28. Persistence of hepatitis B viremia after recovery from acute hepatitis B: correlation between anti-HBc titer and HBV DNA in serum.

31. Response to Interferon of GB Virus C and Hepatitis C Virus in Patients with Chronic Hepatitis.

32. Hepatitis C virus infection in spouses of patients with type C chronic liver disease.

33. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.

Catalog

Books, media, physical & digital resources